Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women. The formulation is intended for use by mouth. As of December 2017, it is in phase III clinical trials for this indication.
See also List of investigational sex-hormonal agents § Estrogenics List of investigational sexual dysfunction drugs
References
External links Acolbifene/prasterone - AdisInsight Pipeline - Endoceutics